he philadelphia chromosome in chronic myelogenous leukemia (CML) gives rise to the BCR-ABL proto-oncogene and its constitutively active protein tyrosine kinase product p210 BCR -ABL . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] BCR-ABL is important because in patients with CML, there is clonal expansion of hematopoietic cells that express this fusion gene. Moreover, continued expression of BCR-ABL is required for sustained proliferation of leukemic cells in mouse models of CML. [6] [7] [8] [9] Imatinib, a potent inhibitor of p210 BCR-ABL , can induce remission in patients with chronic-phase CML, but despite this event, cells in the marrow may continue to produce BCR-ABL transcripts. 17, 18 In some patients, resistance to imatinib develops as a result of BCR-ABL amplification or mutations in the binding site of p210 BCR-ABL for imatinib. 19, 20 In another myeloid leukemia, t(8;21) acute myelogenous leukemia, marrow from patients in complete remission contains apparently normal hematopoietic stem cells that produce AML1-ETO transcripts. The presence of these stem cells during remission suggests that they are preleukemic rather than leukemic cells. (These transcripts participate in the development of acute myeloid leukemia; AML1-ETO is formed by the fusion of part of the AML1 gene on chromosome 8 with part of the ETO gene on chromosome 21. 21 ) Similarly, genomic BCR-ABL persists in the marrow of some patients with CML who are in a sustained complete cytogenetic remission, 22 and it has been detected at very low levels in leukocytes from healthy persons, 23 which suggests that preleukemic hematopoietic stem cells or more differentiated progenitor cells need additional mutations for progression to overt leukemia to occur. 15, 16, [24] [25] [26] In mice, self-renewal of hematopoietic stem cells entails activation of the b -catenin pathway, 27, 28 which results in the translocation of b -catenin to the nucleus, where it interacts with lymphoid enhancer factor/T-cell factor (LEF/TCF) transcription factors and regulates the transcription of genes such as c-myc and cyclin D1. [29] [30] [31] [32] Activating b -catenin mutations occur in many epithelial cancers. [33] [34] [35] [36] [37] The ability to isolate purified populations of hematopoietic stem cells and myeloid progenitors [38] [39] [40] [41] has made it possible to identify genes involved in the self-renewal of hematopoietic stem cells (the ability to make more daughter cells at the same stage of differentiation). 27, 28, [42] [43] [44] [45] Deregulation of self-renewal pathways, which are normally tightly regulated in hematopoietic stem cells, 27, 28, [39] [40] [41] [42] [43] [44] [45] has recently been recognized as an important step in leukemic progression. 46, 47 We conducted a study to identify candidate leukemic stem cells 13, 21, [24] [25] [26] that are responsible for disease progression and resistance to imatinib in patients with CML and to determine whether these stem cells acquire the potential for self-renewal by activating b -catenin. [29] [30] [31] [32] bone marrow and peripheral-blood samples Samples of normal bone marrow (All Cells) or peripheral blood mobilized by granulocyte colonystimulating factor were obtained from 11 healthy volunteers as previously described. 41 Samples were obtained from 20 patients with CML in chronic phase, 26 patients with accelerated-phase CML, and 13 patients with CML in blast crisis. All subjects provided written informed consent, and the study was conducted according to the regulations of the institutional review boards of Stanford University and the University of California, Los Angeles. 41 Cells were obtained from patients before they began treatment with imatinib, from patients who had received imatinib for 6 to 15 months (22 with chronic-phase CML, 11 with accelerated-phase CML, and 2 with CML in blast crisis), and from patients with imatinib-resistant CML (5 with accelerated-phase CML and 1 with CML in blast crisis). Patients with chronic-phase CML received interferon alfa, whereas patients with advanced disease were often treated with cytoreductive agents before receiving imatinib (described in Table 1 (Fig. 1A) . However, an evaluation of individual populations of myeloid progenitors (CD34 + CD38 + Lin ¡ ) revealed that in comparison with normal bone marrow, increased numbers of megakaryocyte-erythroid progenitors were present in marrow from patients with chronicphase CML (P<0.001), levels of common myeloid progenitors were increased in patients with accelerated-phase CML (P=0.004), and levels of granulocyte-macrophage progenitors were increased in marrow from patients with CML in blast crisis (P=0.02) (Fig. 1B) . Among cells from patients with a response to imatinib, there was a significant decrease in the number of CD34 + Lin ¡ cells, as compared with their normal bone marrow counterparts (P=0.03), and the proportion of individual myeloid progenitors reverted to normal, whereas samples from patients with imatinib-resistant CML had increased numbers of granulocyte-macrophage pro- Quantitative RT-PCR analysis demonstrated that in samples from patients with chronic-phase CML, BCR-ABL transcripts were more abundant in hematopoietic stem cells than in myeloid progenitors. Conversely, blast crisis was associated with increased numbers of BCR-ABL transcripts in myeloid progenitors, particularly common myeloid progenitors and granulocyte-macrophage progenitors (Fig. 1C) . Because of the small numbers of progenitors we were able to obtain from banked samples, we performed RT-PCR analysis for BCR-ABL rather than fluorescence in situ hybridization. differ significantly between controls and patients with CML at any stage of the disease. In contrast, myeloid progenitors from patients with CML in an accelerated phase or blast crisis had increased b-catenin levels, as compared with levels in controls ( Fig. 2A) . These levels normalized in patients who had received imatinib (Fig. 2B) . In the absence of phosphorylation, activated b-catenin translocates to the nucleus (Fig. 2 in the Supplementary Appendix).
Confocal fluorescence microscopy with monoclonal antibodies against unphosphorylated b-catenin showed that the staining intensity of nuclear b-catenin was similar in hematopoietic stem cells from controls, patients with accelerated-phase CML, and patients with CML in blast crisis. However, there was a striking increase in activated b-catenin in granulocyte-macrophage progenitors from patients in blast crisis (Fig. 3B) or those who had imatinibresistant CML, as compared with such progenitors from normal marrow (Fig. 3C) . Concordantly, an LEF/TCF-GFP reporter assay of b-catenin-mediated transcriptional activation revealed similar levels of GFP in hematopoietic stem cells from controls, patients with chronic-phase CML (not shown), and patients with CML in blast crisis, but an increase in GFP -and thus in nuclear b-catenin -in granulocyte-macrophage progenitors from patients in blast crisis (Fig. 3D) . Moreover, colonies derived from blast crisis CD34+Lin¡ cells that were transduced with the LEF/TCF-GFP reporter had higher levels of GFP than did their normal counterparts (Fig. 3 in the Supplementary Appendix). Whereas normal granulocyte-macrophage progenitors had reduced expression of b-catenin or its transcriptional coactivator, LEF-1, as compared with normal hematopoietic stem cells, CML granulocyte-macrophage progenitors from patients in blast crisis expressed increased levels of both transcripts (Fig.  4 in the Supplementary Appendix), which most likely contributed to the nuclear accumulation of b-catenin.
self-renewal of cml granulocytemacrophage progenitors
We assessed whether granulocyte-macrophage progenitors in CML gained the high proliferative potential and self-renewal capacity of hematopoietic stem cells as a result of b-catenin activation. [27] [28] [29] [30] [31] [32] CD34 + Lin ¡ cells from patients with CML in the accelerated phase that were transduced with lentiviral b-catenin formed colonies that were larger than normal, whereas transduction of the cells with axin decreased the size of the colonies ( Fig. 4A; and Fig.  5 in the Supplementary Appendix). In addition, enforced expression of b-catenin provided normal granulocyte-macrophage progenitors with selfrenewal capacity in a replating assay (Fig. 4B) . CML granulocyte-macrophage progenitors, but not normal granulocyte-macrophage progenitors, had a high replating capacity and retained the capacity to form myeloid colonies in colony-forming cell assays (Fig. 4C) . Finally, transduction of CML granulocytemacrophage progenitors with axin, an inhibitor of b-catenin signaling, reduced the replating capacity of leukemic cells (Fig. 4C) .
CML is believed to arise as a consequence of the clonal expansion of hematopoietic stem cells that express the BCR-ABL fusion gene. [13] [14] [15] [18] [19] [20] [21] [22] [23] [24] However, recent work with transgenic mouse models of CML showed that although BCR-ABL is necessary for the development of a myeloproliferative syndrome resembling CML, hematopoietic stem cells need not be involved. 8 Moreover, additional genetic or epigenetic events are required for progression to blast crisis. [8] [9] [10] 15, 16 In humans and mice, hematopoietic stem cells are the only normal progenitors that renew themselves, [38] [39] [40] [41] [42] [43] [44] [45] and therefore, they are widely considered to be the only cells in the marrow in which preleukemic changes can accumulate, whether by genetic or epigenetic means. However, it is also possible that a downstream progenitor can acquire self-renewal capacity. [24] [25] [26] [27] 41 It is therefore important to identify the population that contains leukemic stem cells in CML and other myeloid leukemias and to identify events leading to the progression of leukemia, the outcomes of these events, and the order of their appearance in leukemic stem cells and their precursors. [24] [25] [26] Several of our findings in CML cells were unanticipated. First, progression to blast crisis was associated with expansion of the myeloid progenitor fraction, which consists mainly of granulocytemacrophage progenitors, rather than expansion of the pool of hematopoietic stem cells. Second, BCR-ABL amplification occurred in granulocyte-macrophage progenitors, whereas the BCR-ABL transcript levels in hematopoietic stem cells remained relatively constant during progression of the disease. Third, the b-catenin pathway was activated in granulocytemacrophage progenitors from patients with CML in accelerated phase and from those with CML in blast crisis, as well as in patients with imatinib-resistant CML. Fourth, granulocyte-macrophage progenitors in CML have self-renewal capacity, at least in vitro, although our data do not exclude the possibility that this capacity may be more limited than that of normal hematopoietic stem cells in vivo. Fifth, b-catenin-mediated renewal of granulocyte-macrophage progenitors in CML may be inhibited by enforced expression of axin -a potent and highly specific b-catenin antagonist.
We propose that in chronic-phase CML, there is an expansion of the progenitor pool and the downstream progeny of these progenitors that is due in part to the expression of the BCR-ABL fusion gene. This expansion causes the myeloproliferative syndrome (chronic-phase CML), but apoptosis and differentiation pathways remain intact. Progression of 
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CML to blast crisis probably involves several events in primitive progenitors, including BCR-ABL amplification, acquisition of resistance to apoptosis, genomic instability, escape from innate and adaptive immune responses, and activation of b-catenin in granulocyte-macrophage progenitors, resulting in the acquisition of self-renewal capacity (Fig. 5) . 15, 16, [24] [25] [26] 52 Our in vitro replating data indicate that the activation of the self-renewal process by means of the b-catenin pathway in granulocyte-macrophage progenitors, which normally have no capacity for self-renewal, may not only lead to expansion of the granulocyte-macrophage progenitor pool but also play a role in the subsequent production of blasts that occurs in advanced phases of CML, although such blasts may be nonmalignant progeny of leukemic stem cells, rather than leukemic stem cells themselves. The cause of activation of the b-catenin pathway in CML is unknown, and whether b-catenin or other components of the signaling pathway and p210 BCR-ABL interact directly has yet to be determined. Transcriptional targets of b-catenin/LEF-1 signaling, including the cyclin D1 and c-myc genes, also play a critical role in transformation mediated by Abl, a member of the Src kinase family of proto- Unlike the progenitor pool in healthy subjects, in patients with chronic-phase CML, cells within the progenitor pool have an increased proliferative capacity owing to elevated expression of BCR-ABL. This increased proliferative capacity leads to a myeloproliferative syndrome but does not affect the pathways of cell death and differentiation. Progression to blast crisis results from additional events, including the activation of b-catenin in the granulocyte-macrophage progenitor population, increasing their proliferative and self-renewal capacity and possibly allowing them to become leukemic stem cells. Avoidance of cell death, evasion of innate and adaptive immune responses, and a block in differentiation must also occur for CML to progress. Drs. Jamieson, Ailles, and Weissman have applied for a U.S. patent entitled "Use of Beta-Catenin in the Diagnosis and Treatment of Leukemia and Lymphomas" through the Stanford University Office of Technology and Licensing. Dr. Weissman receives consulting fees from and has equity ownership or stock options in Cellerant.
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